BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on E... (ealthy baby boomers this patented natura...)

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

Date:11/10/2008

ealthy baby boomers, this patented natural health brand is expected to address a largely underserved self-care market by providing a scientific, evidence-based health solution. VIVIMIND(TM) is the direct result of over 15 years of significant scientific research, including clinical testing in over 2,000 individuals. Post-hoc analysis of the North American Phase III clinical trial of homotaurine (VIVIMIND(TM)) involving 1,052 Alzheimer's disease (AD) patients showed a positive impact on cognitive function and anatomically it helped to reduce the volume loss of an important area of the brain responsible for memory. VIVIMIND(TM) is commercialized by OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health. The Company's strategy includes revenue generation in the short-to-medium-term through the sale of natural health products and in the medium-to-long-term through development of a pipeline of pharmaceutical products.

Revenue from collaboration agreement amounted to nil for the current quarter ($205,000 for the nine-month period), compared to $228,000 for the same period the previous year ($913,000 for the nine-month period). This revenue was earned under the agreement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product candidate for the treatment of Amyloid A (AA) amyloidosis. During the first quarter of 2008, the Company announced its decision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). The Company expects to file the Investigational New Drug application (IND) in the fourth quarter of 2008, with approximately 190 patients to be followed for a period of 24 months. As part of the decision, the Company withdrew its marketing applications for eprodisate (KIACTA(TM)) in the US, the Eur
'/>"/>

SOURCE BELLUS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine news :

1. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
2. BELLUS Health provides update on activities
3. BELLUS Health announces closing of Innodia acquisition
4. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
5. BELLUS HEALTH reports results for first quarter of fiscal 2008
6. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
7. Healthcare Realty Trust Announces Third Quarter Results
8. World Publics See Government as Responsible for Ensuring Basic Healthcare, Food, and Education Needs
9. MAP Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
10. Major Mental Health Associations Join to Support Give an Hour
11. Wyeth to Present at the Credit Suisse Healthcare Conference

Post Your Comments:

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on E...(ealthy baby boomers this patented natura...),Health